Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-12, Stock:JNJ, The news for the past five days is as follows:
2019-03-05: NEWS1: Why Geron Skyrocketed 27% in February.NEWS2: Why Geron Skyrocketed 27% in February.NEWS3: This ETF Holds Stocks Insiders Want to Own.NEWS4: This ETF Holds Stocks Insiders Want to Own.NEWS5: See inside Johnson & Johnson's new $18M Lake Nona facility (PHOTOS).NEWS6: Health Care Sector Update for 03/05/2019: ADMS, NNVC, NVTA, JNJ, PFE, MRK, ABT, AMGN.NEWS7: Health Care Sector Update for 03/05/2019: ADMS, NNVC, NVTA, JNJ, PFE, MRK, ABT, AMGN.NEWS8: Why Geron Skyrocketed 27% in February.NEWS9: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings.
2019-03-06: NEWS1: Can Smart Beta & Factor ETFs Beat the Market?.NEWS2: Can Smart Beta & Factor ETFs Beat the Market?.NEWS3: Notable Wednesday Option Activity: JNJ, TPX, IR.NEWS4: Notable Wednesday Option Activity: JNJ, TPX, IR.NEWS5: Can Smart Beta & Factor ETFs Beat the Market?.NEWS6: FDA Commissioner Gottlieb resigns.NEWS7: Dow Falls as Investors Eye Details From Trade Talks, Oil Prices Tumble.NEWS8: J&J prices ketamine-like depression treatment at $590-$885 for two doses.NEWS9: Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important.NEWS10: J&J prices ketamine-like depression treatment at $590-$885 for two doses.NEWS11: Ketamine-Like Depression Drug Isn’t a Surefire Hit.NEWS12: U.S. FDA finds asbestos in three Claire's cosmetics products.NEWS13: The Late Morning Rundown: March 06, 2019.NEWS14: Johnson & Johnson Edges Higher After FDA Approves Nasal Spray Antidepressant.NEWS15: Can Gilead Sciences Return to Winning Ways?.NEWS16: J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression.NEWS17: J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression.NEWS18: Jim Cramer Keeping an Eye on Dollar Tree, GE and Johnson & Johnson.NEWS19: Dow Turns Lower as Investors Eye Details From Trade Talks.NEWS20: Jim Cramer: What to Watch from GE, Johnson & Johnson and Dollar Tree.NEWS21: Health Care Sector Update for 03/06/2019: VLRX, OPTN, INFI, JNJ, PFE, MRK, ABT, AMGN.NEWS22: Health Care Sector Update for 03/06/2019: VLRX, OPTN, INFI, JNJ, PFE, MRK, ABT, AMGN.NEWS23: Stocks Fade Ahead Of Fed Data; This Dow Jones Stock Gets FDA Boost.NEWS24: Stocks Open Mixed; This Dow Jones Stock Gets FDA Boost.NEWS25: Dow Edges Higher but Wall Street Is Mixed as Investors Eye Trade Talks.NEWS26: FDA Approves Major Novel Depression Drug For First Time In 3 Decades.NEWS27: J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression.NEWS28: Stock Futures Ease; This Dow Jones Stock Gets FDA Boost.NEWS29: Stocks making the biggest moves premarket: General Electric, BJ's Wholesale, TripAdvisor & more.NEWS30: Johnson & Johnson, General Electric, NIO, Abercrombie - 5 Things You Must Know.NEWS31: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split.NEWS32: Market Morning: FDA Head Resigns, India Strikes Out, Special K Approved, Trade Deficit Explodes.NEWS33: Stocks - GE Slides in Premarket, Abercrombie and Fitch, Dollar Tree Soar.NEWS34: FDA allows treatment of depression with club drug's cousin.NEWS35: FDA allows treatment of depression with club drug's cousin.NEWS36: [$$] FDA Approves Controversial Drug for Depression.NEWS37: [$$] US approves first depression drug in decades.NEWS38: J&J nasal spray gets U.S. approval as first new type of anti-depressant in decades.NEWS39: Mind-altering, ketamine-like drug OK'd for severe depression.NEWS40: FDA approves J&J's ketamine-like nasal spray for depression.NEWS41: FDA approves Johnson & Johnson’s ketamine-like drug to treat severe depression.NEWS42: FDA approves J&J's ketamine-like nasal spray for depression.NEWS43: Trippy ketamine-like drug approved for severe depression.
2019-03-07: NEWS1: Why News From J&J, Allergan Could Be A Boon For This Biotech Stock.NEWS2: Monthly shots control HIV as well as pills in 2 big studies.NEWS3: Monthly shots control HIV as well as pills in 2 big studies.NEWS4: Allergan's Depression Candidate Fails in Studies, Stock Down.NEWS5: Allergan's Depression Candidate Fails in Studies, Stock Down.NEWS6: Take Profits Now and Buy Shopify Stock on Its Next Big Dip.NEWS7: Allergan's Depression Drug Letdown Largely Expected: Analysts Focus On Remainder Of Pipeline.NEWS8: Allergan Rises After FDA Accepts License Applications for Botox Supplements.NEWS9: Health Care Sector Update for 03/07/2019: GTXI, BPTH, CODX, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Health Care Sector Update for 03/07/2019: GTXI, BPTH, CODX, JNJ, PFE, ABT, MRK, AMGN.NEWS11: Allergan Recovers After Depression Treatment Candidate Fails Study.NEWS12: Allergan's Depression Candidate Fails in Studies, Stock Down.NEWS13: Allergan Falls After Depression Treatment Candidate Fails Study.NEWS14: 2 Biotech Stocks With Major Incoming Catalysts.NEWS15: 2 Biotech Stocks With Major Incoming Catalysts.NEWS16: 2 Biotech Stocks With Major Incoming Catalysts.
2019-03-08: NEWS1: Can Smart Beta & Factor ETFs Beat the Market?.NEWS2: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS3: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS4: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS5: How to Invest in Woman-Led Companies With ETFs & Stocks.NEWS6: How to Invest in Woman-Led Companies With ETFs & Stocks.NEWS7: Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up.NEWS8: Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up.NEWS9: Major consumer companies make few gains in female representation in board rooms.NEWS10: Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up.NEWS11: Health Care Sector Update for 03/08/2019: SEEL, ACET, ARDX, JNJ, PFE, ABT, MRK, AMGN.NEWS12: Health Care Sector Update for 03/08/2019: SEEL, ACET, ARDX, JNJ, PFE, ABT, MRK, AMGN.NEWS13: How to Invest in Woman-Led Companies With ETFs & Stocks.NEWS14: Can Google’s YouTube Still Hit $11.4 Billion in Revenue in 2019?.NEWS15: Cramer: A potential 'blockbuster win' for owners of Johnson & Johnson.NEWS16: Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving.
2019-03-11: NEWS1: Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know.NEWS2: Health Care Sector Update for 03/11/2019: JNJ,ELAN,LLY,AXGT,CRON,CRON.TO.NEWS3: Health Care Sector Update for 03/11/2019: JNJ,ELAN,LLY,AXGT,CRON,CRON.TO.NEWS4: Bayer Submits Application in EU for Prostate Cancer Drug.NEWS5: Bayer Submits Application in EU for Prostate Cancer Drug.NEWS6: Bayer Submits Application in EU for Prostate Cancer Drug.NEWS7: Johnson & Johnson Buys Large Stake in MeiraGTx.NEWS8: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS9: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS10: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS11: Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN.NEWS12: Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN.NEWS13: Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February.NEWS14: Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February.NEWS15: Here&apos;s Why Arrowhead Pharmaceuticals Gained 38.2% in February.

Answer: Rise